<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04974281</url>
  </required_header>
  <id_info>
    <org_study_id>HUASHAN007</org_study_id>
    <nct_id>NCT04974281</nct_id>
  </id_info>
  <brief_title>PD-1 Antibody and Lenvatinib Plus TACE on Downstaging BCLC B/C HCC</brief_title>
  <official_title>Efficacy and Safety of PD-1 Antibody and Lenvatinib Plus TACE on Downstaging Hepatocellular Carcinoma With BCLC B/C</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the difference of safety and efficacy about PD-1&#xD;
      Antibody and Lenvatinib Plus transcatheter arterial chemoembolization (TACE) on downstaging&#xD;
      hepatocellular carcinoma with BCLC B/C.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Resection rate</measure>
    <time_frame>6 months after downstaging treatment</time_frame>
    <description>Resction rate refers to the proportion of patients who can receive radical surgery after downstaging treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events (safety)</measure>
    <time_frame>6 months</time_frame>
    <description>Postoperative adverse events (safety ) will be evaluated according to the NCI CTCAE Version 4.03.The number and severity of treatment-related side effects, including AE and SAE, will be recorded during treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>2 years</time_frame>
    <description>The duration from the date of recruitment to the date of death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>6 months</time_frame>
    <description>ORR is defined as the percentage of participants who have a confirmed complete response or partial response according to RECIST 1.1 or mRECIST.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>6 months</time_frame>
    <description>PFS is defined as the time from enrollment of the trial to the first documented disease progression or death due to any cause.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>PD-1+TACE+Len</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>PD-1 Antibody and Lenvatinib Plus TACE</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>PD-1 and Lenvatinib Plus TACE</intervention_name>
    <description>PD-1 Antibody and Lenvatinib Plus Transarterial chemoembolization(TACE )： Patients were recommended to receive TACE once every 6 weeks. Patients were recommended to begin oral administration of Lenvatinib 3 days after the first TACE treatment, and meanwhile to start intravenous drip of PD-1 antibody 3 days after the first TACE treatment, once every 3 weeks.</description>
    <arm_group_label>PD-1+TACE+Len</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥18 years old and ≤75 years old;&#xD;
&#xD;
          2. Clinically diagnosed as hepatocellular carcinoma, stage B/C of BCLC;&#xD;
&#xD;
          3. No history of severe arrhythmia or heart failure;&#xD;
&#xD;
          4. No history of severe ventilation dysfunction or severe pulmonary infection;&#xD;
&#xD;
          5. No acute or chronic renal failure, the creatinine clearance rate was &gt;40 mL/min;&#xD;
&#xD;
          6. Liver function Child A;&#xD;
&#xD;
          7. Blood routine: absolute neutrophils count ≥1.5×10^9/L, Hb≥8.5g/L, PLT≥75×10^9/L;&#xD;
&#xD;
          8. Coagulation function: INR≤2.3;&#xD;
&#xD;
          9. ECOG score &lt;2;&#xD;
&#xD;
         10. No local or systemic treatment, such as TACE, RFA, targeted drugs, traditional Chinese&#xD;
             medicine, etc., before enrollment;&#xD;
&#xD;
         11. Expected survival ≥12 weeks;&#xD;
&#xD;
         12. At least one lesion can be measured and evaluated by CT/MRI according to RECIST 1.1&#xD;
             criteria;&#xD;
&#xD;
         13. Understand and sign the informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or lactating women;&#xD;
&#xD;
          2. Patients with other malignant tumors;&#xD;
&#xD;
          3. patients with complicated mental illness;&#xD;
&#xD;
          4. patients who have participated in other clinical trials in the last three months;&#xD;
&#xD;
          5. known or suspected allergy to any drug related to the study;&#xD;
&#xD;
          6. Patients with positive immunodeficiency virus (HIV) or acquired immunodeficiency&#xD;
             syndrome (AIDS)&#xD;
&#xD;
          7. Patients treated with other targeted drugs, PD-L1 antibody and other immunotherapy or&#xD;
             FOLFOX systemic chemotherapy after inclusion;&#xD;
&#xD;
          8. Patients with ≥1 + proteinuria indicated by urine routine will receive 24-hour urine&#xD;
             protein detection, and patients with ≥1g 24-hour urine protein will not be included in&#xD;
             the group.&#xD;
&#xD;
          9. Active autoimmune diseases that require systemic treatment (use of disease-alleviating&#xD;
             agents, such as corticosteroids or immunosuppressants)&#xD;
&#xD;
         10. Patients with uncontrolled hepatitis B/C infection&#xD;
&#xD;
         11. Other conditions that the researcher considers not suitable for inclusion in this&#xD;
             study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lunxiu Qin, M.D</last_name>
    <role>Study Director</role>
    <affiliation>Department of Surgery, Huashan Hospital, Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lunxiu Qin, M.D</last_name>
    <phone>+862152887172</phone>
    <email>qinlx99@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Huashan hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ying Zhu, Ph.D</last_name>
      <phone>+862152887175</phone>
      <email>yzhu14@fudan.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Lu Lu, M.D</last_name>
      <phone>+862152887174</phone>
      <email>lulu@huashan.org.cn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12. Erratum in: CA Cancer J Clin. 2020 Jul;70(4):313.</citation>
    <PMID>30207593</PMID>
  </reference>
  <reference>
    <citation>Lencioni R, de Baere T, Soulen MC, Rilling WS, Geschwind JF. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data. Hepatology. 2016 Jul;64(1):106-16. doi: 10.1002/hep.28453. Epub 2016 Mar 7. Review.</citation>
    <PMID>26765068</PMID>
  </reference>
  <reference>
    <citation>Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, Park JW, Han G, Jassem J, Blanc JF, Vogel A, Komov D, Evans TRJ, Lopez C, Dutcus C, Guo M, Saito K, Kraljevic S, Tamai T, Ren M, Cheng AL. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018 Mar 24;391(10126):1163-1173. doi: 10.1016/S0140-6736(18)30207-1.</citation>
    <PMID>29433850</PMID>
  </reference>
  <reference>
    <citation>Kato Y, Tabata K, Kimura T, Yachie-Kinoshita A, Ozawa Y, Yamada K, Ito J, Tachino S, Hori Y, Matsuki M, Matsuoka Y, Ghosh S, Kitano H, Nomoto K, Matsui J, Funahashi Y. Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway. PLoS One. 2019 Feb 27;14(2):e0212513. doi: 10.1371/journal.pone.0212513. eCollection 2019.</citation>
    <PMID>30811474</PMID>
  </reference>
  <reference>
    <citation>Kudo M, Ueshima K, Ikeda M, Torimura T, Tanabe N, Aikata H, Izumi N, Yamasaki T, Nojiri S, Hino K, Tsumura H, Kuzuya T, Isoda N, Yasui K, Aino H, Ido A, Kawabe N, Nakao K, Wada Y, Yokosuka O, Yoshimura K, Okusaka T, Furuse J, Kokudo N, Okita K, Johnson PJ, Arai Y; TACTICS study group. Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. Gut. 2020 Aug;69(8):1492-1501. doi: 10.1136/gutjnl-2019-318934. Epub 2019 Dec 4.</citation>
    <PMID>31801872</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 20, 2021</study_first_submitted>
  <study_first_submitted_qc>July 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2021</study_first_posted>
  <last_update_submitted>July 13, 2021</last_update_submitted>
  <last_update_submitted_qc>July 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Lunxiu Qin</investigator_full_name>
    <investigator_title>Director, Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>Lenvatinib</keyword>
  <keyword>PD-1</keyword>
  <keyword>TACE</keyword>
  <keyword>Downstaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenvatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

